Jazz Pharmaceuticals Licenses PharmaMar’s Lung Cancer Drug Lurbinectedin

By Michelle Liu

Pharma Deals Review: Vol 2019 Issue 12 (Table of Contents)

Published: 24 Dec-2019

DOI: 10.3833/pdr.v2019.i12.2479     ISSN: 1756-7874

Section: Licensing



In a bid to expand its oncology portfolio, Jazz Pharmaceuticals has agreed to license the US rights todevelop and commercialise lurbinectedin from PharmaMar in a deal worth up to US$1 B...

This page is available to subscribers only.

Not a subscriber? Join here

Why should I subscribe?

Already Registered? Please login using the top left purple box.

Copyright: © IQVIA 2018

IQVIA™ Pharma Deals: PharmaDeals Review: Article Details